Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CAPR
Previous SymbolNASDAQ:NLTX
CUSIPN/A
Phone310-358-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio6.09
Quick Ratio6.09
Price-To-Earnings
Trailing P/E Ratio-1.17
Forward P/E Ratio-0.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.67 million
Price / Sales5.97
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.44 per share
Price / Book1.17
Profitability
EPS (Most Recent Fiscal Year)($0.44)
Net Income$2.43 million
Net Margins24.75%
Return on Equity-159.36%
Return on Assets-105.04%
Miscellaneous
Employees40
Outstanding Shares31,070,000
Market Cap$16.47 million
OptionableNot Optionable
Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."
How were Capricor Therapeutics' earnings last quarter?
Capricor Therapeutics Inc (NASDAQ:CAPR) released its quarterly earnings data on Tuesday, November, 13th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.01. The biotechnology company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.90 million. Capricor Therapeutics had a negative return on equity of 159.36% and a net margin of 24.75%. View Capricor Therapeutics' Earnings History.
When is Capricor Therapeutics' next earnings date?
What price target have analysts set for CAPR?
2 brokers have issued 1 year price objectives for Capricor Therapeutics' shares. Their predictions range from $4.00 to $9.00. On average, they anticipate Capricor Therapeutics' share price to reach $6.50 in the next twelve months. This suggests a possible upside of 1,166.1% from the stock's current price. View Analyst Price Targets for Capricor Therapeutics.
What is the consensus analysts' recommendation for Capricor Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Capricor Therapeutics.
What are Wall Street analysts saying about Capricor Therapeutics stock?
Here are some recent quotes from research analysts about Capricor Therapeutics stock:
- 1. According to Zacks Investment Research, "Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. " (12/7/2018)
- 2. HC Wainwright analysts commented, "Valuation and potential impediments to achieving it. We reiterate our Buy rating and $8.60 price target. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, CAP-1002 in DMD patients. We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch." (11/20/2018)
- 3. Maxim Group analysts commented, "Capricor reported 3Q18 with a net loss of ($4.1M) and ended the period with $10.4M in cash on the balance sheet, runway into 2Q18. We do expect that the company will need to raise capital in early 2019, prior to reaching data for the HOPE-2 study, which is expected in 2020." (11/14/2018)
Has Capricor Therapeutics been receiving favorable news coverage?
News articles about CAPR stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Capricor Therapeutics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an impact on the company's share price in the next several days.
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include Processa Pharmaceuticals (PCSA), vTv Therapeutics (VTVT), NewLink Genetics (NLNK), IMMUTEP LTD/S (IMMP), Bellerophon Therapeutics (BLPH), Sophiris Bio (SPHS), Neos Therapeutics (NEOS), KemPharm (KMPH), BioXcel Therapeutics (BTAI), Arcturus Therapeutics (ARCT), Fortress Biotech (FBIO), Ophthotech (OPHT), Avenue Therapeutics (ATXI), Merrimack Pharmaceuticals (MACK) and Aquinox Pharmaceuticals (AQXP).
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
- Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
- Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
- Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
- Deborah Ascheim M.D., Chief Medical Officer
- Joshua A. Kazam, Director (Age 40)
Who are Capricor Therapeutics' major shareholders?
Capricor Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Brown Advisory Inc. (2.99%). Company insiders that own Capricor Therapeutics stock include Louis Manzo and Sinai Medical Center Cedars. View Institutional Ownership Trends for Capricor Therapeutics.
Which major investors are selling Capricor Therapeutics stock?
How do I buy shares of Capricor Therapeutics?
Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
One share of CAPR stock can currently be purchased for approximately $0.5134.
How big of a company is Capricor Therapeutics?
Capricor Therapeutics has a market capitalization of $16.47 million and generates $2.67 million in revenue each year. The biotechnology company earns $2.43 million in net income (profit) each year or ($0.44) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.
What is Capricor Therapeutics' official website?
How can I contact Capricor Therapeutics?
Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]
MarketBeat Community Rating for Capricor Therapeutics (NASDAQ CAPR)
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
